StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$3.44−0.15 (-4.18%)

Close on Nov 13, 2026Market cap $13.93MP/E 0.1Yield –

Kyntra Bio gross margin

Gross margin is gross profit as a percentage of revenue.

Kyntra Bio's gross margin for the twelve months ending Jun 30, 2026 was 6.3%. For fiscal 2025 it was 91.4%, against 47.5% the year before. The highest annual figure on record is 99.6% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202591.4%+43.9
FY2024Dec 31, 202447.5%−44.1
FY2023Dec 31, 202391.5%+5.9
FY2022Dec 31, 202285.6%−8.9
FY2021Dec 31, 202194.5%−0.4
FY2020Dec 31, 202095.0%−4.6
FY2019Dec 31, 201999.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-9.8%−100.6
Q4 FY2025Dec 31, 202578.2%−82.7
Q3 FY2025Sep 30, 2025105.4%+19.4
Q2 FY2025Jun 30, 202593.7%+77.8
Q1 FY2025Mar 31, 202590.8%+10.7
Q3 FY2024Sep 30, 2024161.0%+71.5
Q2 FY2024Jun 30, 202486.0%−1.1
Q1 FY2024Mar 31, 202415.9%−74.5
Q4 FY2023Dec 31, 202380.1%−5.6
Q3 FY2023Sep 30, 202389.4%+16.8
Q2 FY2023Jun 30, 202387.1%+10.0
Q1 FY2023Mar 31, 202390.3%−2.7
Q4 FY2022Dec 31, 202285.7%+4.6
Q3 FY2022Sep 30, 202272.6%−25.3
Q2 FY2022Jun 30, 202277.2%−10.2
Q1 FY2022Mar 31, 202293.0%+1.9
Q4 FY2021Dec 31, 202181.1%−14.9
Q3 FY2021Sep 30, 202197.9%+2.9
Q2 FY2021Jun 30, 202187.4%–
Q1 FY2021Mar 31, 202191.1%–
Q4 FY2020Dec 31, 202096.0%–
Q3 FY2020Sep 30, 202095.0%–

More Kyntra Bio figures

See a number that looks wrong?